Boston Scientific Corporation $BSX Shares Sold by Stevens Capital Management LP

Key Points

• Stevens Capital Management trimmed its stake in Boston Scientific by 25.6% in Q4, selling 18,535 shares and leaving it with 53,761 shares valued at about $5.13 million (BSX is its 10th-largest holding).
• Boston Scientific slightly beat Q1 estimates (EPS $0.80 vs. $0.79; revenue $5.20B vs. $5.19B) and set Q2 guidance of $0.820–0.840 EPS and FY2026 guidance of $3.340–3.410, with analysts projecting ~$3.38 for the year.
• The stock opened near $55.98 (around its 1-year low), was down ~1.5%, has a market cap of about $83.2B, and carries a consensus rating of Moderate Buy with an average price target of $93.91.

Stevens Capital Management LP trimmed its holdings in Boston Scientific Corporation (NYSE:BSX - Free Report) by 25.6% in the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 53,761 shares of the medical equipment provider's stock after selling 18,535 shares during the period. Boston Scientific makes up about 1.8% of Stevens Capital Management LP's holdings, making the stock its 10th largest holding. Stevens Capital Management LP's holdings in Boston Scientific were worth $5,126,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Vanguard Group Inc. raised its position in Boston Scientific by 0.8% in the third quarter. Vanguard Group Inc. now owns 138,249,447 shares of the medical equipment provider's stock valued at $13,497,294,000 after purchasing an additional 1,115,337 shares during the period. Rathbones Group PLC boosted its position in shares of Boston Scientific by 20.9% during the fourth quarter. Rathbones Group PLC now owns 2,759,657 shares of the medical equipment provider's stock worth $263,133,000 after buying an additional 477,680 shares during the period. Gladstone Institutional Advisory LLC grew its stake in shares of Boston Scientific by 39.5% in the third quarter. Gladstone Institutional Advisory LLC now owns 51,884 shares of the medical equipment provider's stock valued at $5,065,000 after buying an additional 14,700 shares in the last quarter. Kepler Cheuvreux Suisse SA purchased a new stake in shares of Boston Scientific in the 3rd quarter valued at $26,955,000. Finally, Tounjian Advisory Partners LLC acquired a new position in Boston Scientific during the 4th quarter worth about $1,477,000. Institutional investors and hedge funds own 89.07% of the company's stock.

Boston Scientific Trading Down 1.5%

NYSE:BSX opened at $55.98 on Wednesday. Boston Scientific Corporation has a 1 year low of $55.88 and a 1 year high of $109.50. The stock has a market cap of $83.20 billion, a P/E ratio of 23.42, a P/E/G ratio of 1.04 and a beta of 0.62. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.08 and a current ratio of 1.90. The stock has a 50-day simple moving average of $66.69 and a 200-day simple moving average of $84.28.

Boston Scientific (NYSE:BSX - Get Free Report) last posted its earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share for the quarter, topping the consensus estimate of $0.79 by $0.01. The firm had revenue of $5.20 billion during the quarter, compared to analysts' expectations of $5.19 billion. Boston Scientific had a return on equity of 19.17% and a net margin of 17.29%.The firm's revenue was up 11.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.75 earnings per share. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. As a group, analysts anticipate that Boston Scientific Corporation will post 3.38 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have weighed in on BSX shares. The Goldman Sachs Group dropped their target price on Boston Scientific from $87.00 to $84.00 and set a "buy" rating for the company in a research report on Wednesday, April 22nd. Raymond James Financial reissued an "outperform" rating and set a $88.00 price target (down from $97.00) on shares of Boston Scientific in a research report on Monday, March 30th. Argus upgraded shares of Boston Scientific to a "strong-buy" rating in a report on Thursday, February 26th. Sanford C. Bernstein reaffirmed an "outperform" rating and set a $112.00 target price on shares of Boston Scientific in a research note on Friday, February 6th. Finally, TD Cowen reduced their target price on shares of Boston Scientific from $115.00 to $100.00 and set a "buy" rating on the stock in a report on Monday, February 2nd. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and three have given a Hold rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $93.91.

About Boston Scientific

Boston Scientific Corporation NYSE: BSX is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific's activities span product development, clinical research, regulatory affairs and commercial sales.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.